UBS Group’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $74.8M | Buy |
843,071
+171,836
| +26% | +$12.5M | 0.01% | 1352 |
|
|
2026
Q1 | $33.9M | Sell |
671,235
-9,331
| -1% | -$352K | 0.01% | 2042 |
|
|
2025
Q4 | $22.3M | Buy |
680,566
+294,977
| +77% | +$7.71M | ﹤0.01% | 2487 |
|
|
2025
Q3 | $6.46M | Sell |
385,589
-77,274
| -17% | -$1.26M | ﹤0.01% | 3775 |
|
|
2025
Q2 | $6.93M | Sell |
462,863
-89,380
| -16% | -$1.32M | ﹤0.01% | 3518 |
|
|
2025
Q1 | $8.91M | Buy |
552,243
+160,046
| +41% | +$3.33M | ﹤0.01% | 3164 |
|
|
2024
Q4 | $9.13M | Buy |
392,197
+334,359
| +578% | +$9.8M | ﹤0.01% | 3160 |
|
|
2024
Q3 | $1.7M | Buy |
57,838
+13,334
| +30% | +$371K | ﹤0.01% | 4157 |
|
|
2024
Q2 | $1.05M | Buy |
44,504
+41,903
| +1,611% | +$1.41M | ﹤0.01% | 4392 |
|
|
2024
Q1 | $98.7K | Sell |
2,601
-1,125
| -30% | -$32.6K | ﹤0.01% | 6234 |
|
|
2023
Q4 | $80.2K | Buy |
+3,726
| New | +$51.3K | ﹤0.01% | 6299 |
|
|
2023
Q3 | – | Sell |
-324
| Closed | -$3.65K | – | 9952 |
|
|
2023
Q2 | $3.65K | Buy |
+324
| New | +$1.54K | ﹤0.01% | 7612 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 9510 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 10619 |
|
|
2022
Q3 | – | Sell |
-3,072
| Closed | -$39K | – | 10900 |
|
|
2022
Q2 | $39K | Buy |
3,072
+461
| +18% | +$16.2K | ﹤0.01% | 6122 |
|
|
2022
Q1 | $150K | Sell |
2,611
-2,854
| -52% | -$240K | ﹤0.01% | 5594 |
|
|
2021
Q4 | $649K | Buy |
5,465
+3,296
| +152% | +$520K | ﹤0.01% | 4765 |
|
|
2021
Q3 | $431K | Buy |
2,169
+86
| +4% | +$15K | ﹤0.01% | 4826 |
|
|
2021
Q2 | $362K | Buy |
2,083
+84
| +4% | +$15.3K | ﹤0.01% | 4955 |
|
|
2021
Q1 | $396K | Buy |
1,999
+185
| +10% | +$35.5K | ﹤0.01% | 5041 |
|
|
2020
Q4 | $357K | Buy |
1,814
+323
| +22% | +$66.9K | ﹤0.01% | 4853 |
|
|
2020
Q3 | $264K | Sell |
1,491
-252
| -14% | -$46.6K | ﹤0.01% | 4627 |
|
|
2020
Q2 | $403K | Sell |
1,743
-18
| -1% | -$3.43K | ﹤0.01% | 4321 |
|
|
2020
Q1 | $205K | Sell |
1,761
-439
| -20% | -$74.7K | ﹤0.01% | 4706 |
|
|
2019
Q4 | $420K | Sell |
2,200
-147
| -6% | -$28.9K | ﹤0.01% | 4991 |
|
|
2019
Q3 | $451K | Buy |
2,347
+637
| +37% | +$124K | ﹤0.01% | 4649 |
|
|
2019
Q2 | $293K | Buy |
1,710
+26
| +2% | +$4.49K | ﹤0.01% | 4668 |
|
|
2019
Q1 | $339K | Sell |
1,684
-21
| -1% | -$4.38K | ﹤0.01% | 4305 |
|
|
2018
Q4 | $319K | Sell |
1,705
-422
| -20% | -$89.5K | ﹤0.01% | 4584 |
|
|
2018
Q3 | $509K | Sell |
2,127
-834
| -28% | -$195K | ﹤0.01% | 4384 |
|
|
2018
Q2 | $784K | Buy |
2,961
+1,978
| +201% | +$487K | ﹤0.01% | 3971 |
|
|
2018
Q1 | $244K | Buy |
983
+930
| +1,755% | +$168K | ﹤0.01% | 4654 |
|
|
2017
Q4 | $7K | Sell |
53
-25
| -32% | -$3.06K | ﹤0.01% | 7242 |
|
|
2017
Q3 | $10K | Sell |
78
-26
| -25% | -$2.44K | ﹤0.01% | 6896 |
|
|
2017
Q2 | $10K | Buy |
104
+65
| +167% | +$8.99K | ﹤0.01% | 6781 |
|
|
2017
Q1 | $7K | Buy |
39
+7
| +22% | +$988 | ﹤0.01% | 6829 |
|
|
2016
Q4 | $3K | Sell |
32
-663
| -95% | -$96.7K | ﹤0.01% | 7430 |
|
|
2016
Q3 | $112K | Buy |
695
+407
| +141% | +$56.6K | ﹤0.01% | 4928 |
|
|
2016
Q2 | $35K | Buy |
+288
| New | +$55.2K | ﹤0.01% | 5811 |
|
Other funds holding SYRE
PA
RI
PBA
VA
DCM
UBS Group's SYRE Position: Q2 2026 in Review
UBS Group increased its Spyre Therapeutics (SYRE) stake by 26% in Q2 2026, buying an estimated $12.5M and bringing the position to 843,071 shares worth $74.8M. The position accounts for 0.01% of the portfolio, ranked #1352.
UBS Group first reported a position in SYRE in Q2 2016 and has held it in 37 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.
- UBS Group held 843,071 shares of Spyre Therapeutics worth $74.8M as of Q2 2026.
- UBS Group bought 171,836 Spyre Therapeutics shares in Q2 2026, an estimated $12.5M.
- Spyre Therapeutics made up 0.01% of UBS Group's portfolio in Q2 2026, its #1352 holding.
- UBS Group first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 37 quarters since.
- 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.